Study #2022-0556
A Phase 2 study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamic of Narsoplimab in Pediatric patients (28 Days to 18 Y.O.) with high risk Haematopoietic Stem Cell Transplant Thrombotic Microangiopathy
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Jeremy Connors
Department:
Pediatrics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.